Safety, PK, PD, and Antitumor Activity of Vecabrutinib (SNS-062) in B Lymphoid Cancers
Stopped early · Phase 1/Phase 2
Conditions studied: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Lymphoplasmacytoid Lymphoma, Mantle-Cell Lymphoma, Waldenstrom Macroglobulinemia, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Marginal Zone Lymphoma
In brief
This is an open-label Phase 1b/2 study in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)or non hodgkin's lymphoma (NHL) who have failed prior standard of care therapies including a BTK inhibitor where one is approved for the indication.
Key facts
- Study ID
- NCT03037645
- Run by
- Sunesis Pharmaceuticals
- People needed
- 39
- Starts
- 2017-04-28
- Expected to finish
- 2020-08-31
- Last updated by the study team
- 2020-10-19
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- University of California Irvine Medical Center — Orange, California, United States
- UC San Diego Moores Cancer Center — San Diego, California, United States
- Moffitt Cancer Center and Research Institute — Tampa, Florida, United States
- The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins — Baltimore, Maryland, United States
- Dana-Farber Cancer Institute — Boston, Massachusetts, United States
- Weill Cornell Medicine — New York, New York, United States
- Willamette Valley Cancer Institute and Research Center — Eugene, Oregon, United States
- MD Anderson Cancer Center — Houston, Texas, United States
- Texas Oncology - Tyler — Tyler, Texas, United States
- Swedish Cancer Institute — Seattle, Washington, United States
- Fred Hutchinson Cancer Research Center — Seattle, Washington, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.